Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3816221 | 0.88 | TLR7 (0.65) | TLR7TLR8 | |
| SCHEMBL27764961 | 0.81 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL6107457 | 0.81 | TLR7 (0.50) | TLR7TLR8 | |
| SCHEMBL728302 | 0.79 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL728266 | 0.79 | TLR7 (0.80) | TLR7TLR8 | |
| Water SCHEMBL10736495 | 0.78 | TLR7 (0.58) | TLR7TLR8 | |
| SCHEMBL10738089 | 0.77 | TLR7 (0.54) | TLR7TLR8 | |
| SCHEMBL28413158 | 0.77 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL5746883 | 0.77 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL5347638 | 0.77 | TLR7 (0.53) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4833466-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-1198233-B1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1198233-A4 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2002-07-24 | — | — | EP | claimed |
| EP-1198233-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2002-04-24 | — | — | EP | claimed |
| WO-2000076519-A1 | SULFONAMIDE AND SULFAMIDE SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-12-21 | — | — | WO | claimed |